Market Overview

Here's Why Shares Of TrovaGene Are Surging

Share:

Shares of TrovaGene Inc (NASDAQ: TROV), a development-stage molecular diagnostic company, were trading higher by nearly 20 percent on Monday after the company announced that it has entered into an agreement with FedMEd, a proprietary Preferred Provider Organization consisting of over 550,000 Physicians.

As part of the agreement, FedMed will have access to Trovagene's full line of Precision Cancer Monitoring (PCM) test and services. In addition, the company's PCM services will be covered as a participating laboratory testing provider for clients of FedMed.

Trovagene's PCM services is designed to "provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally."

"FedMed is among the largest national provider networks in the country, and this agreement is an important step in our ability to offer oncologists and their patients access to our liquid biopsy testing services through their health benefit plans," said Matt Posard, chief commercial officer of Trovagene. "We're very pleased with the positive response we are receiving from national provider networks, validating our decision to design the PCM platform to report on clinically actionable cancer genes that can translate into clear use scenarios and better reimbursement outcomes. We remain committed to creating a strong foundation of studies demonstrating the multiple clinical utilities of our technology, which we believe will broaden health insurance coverage and patient access this year."

Posted-In: Cancer Detection Cancer Therapies FedMed Health Insurance Health stocks Matt PosardNews Movers

 

Related Articles (TROV)

View Comments and Join the Discussion!
Fastest Market News Application
You'll Hear It First On Pro
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Report: Apple Could Consider Bid For Netflix

Stock Marquee is Crowded in Week Ahead: Oil, Earnings, Labor Data